Logo image of SALME.OL

SALMON EVOLUTION ASA (SALME.OL) Stock Fundamental Analysis

Europe - OSL:SALME - NO0010892094 - Common Stock

5.2 NOK
-0.05 (-0.95%)
Last: 9/12/2025, 7:00:00 PM
Fundamental Rating

2

SALME gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 59 industry peers in the Food Products industry. Both the profitability and financial health of SALME have multiple concerns. SALME is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SALME had negative earnings in the past year.
In the past year SALME has reported a negative cash flow from operations.
SALME had negative earnings in each of the past 5 years.
In the past 5 years SALME reported 4 times negative operating cash flow.
SALME.OL Yearly Net Income VS EBIT VS OCF VS FCFSALME.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M

1.2 Ratios

SALME has a worse Return On Assets (-5.15%) than 81.36% of its industry peers.
Looking at the Return On Equity, with a value of -8.41%, SALME is doing worse than 76.27% of the companies in the same industry.
Industry RankSector Rank
ROA -5.15%
ROE -8.41%
ROIC N/A
ROA(3y)-2.76%
ROA(5y)-2.34%
ROE(3y)-3.94%
ROE(5y)-3.2%
ROIC(3y)N/A
ROIC(5y)N/A
SALME.OL Yearly ROA, ROE, ROICSALME.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

SALME has a better Gross Margin (62.88%) than 91.53% of its industry peers.
SALME's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SALME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.83%
GM growth 5YN/A
SALME.OL Yearly Profit, Operating, Gross MarginsSALME.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

SALME does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SALME has been increased compared to 1 year ago.
SALME has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SALME has an improved debt to assets ratio.
SALME.OL Yearly Shares OutstandingSALME.OL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
SALME.OL Yearly Total Debt VS Total AssetsSALME.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

SALME has an Altman-Z score of 0.95. This is a bad value and indicates that SALME is not financially healthy and even has some risk of bankruptcy.
SALME's Altman-Z score of 0.95 is on the low side compared to the rest of the industry. SALME is outperformed by 81.36% of its industry peers.
SALME has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SALME (0.41) is better than 66.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 0.95
ROIC/WACCN/A
WACC7.83%
SALME.OL Yearly LT Debt VS Equity VS FCFSALME.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

SALME has a Current Ratio of 0.96. This is a bad value and indicates that SALME is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of SALME (0.96) is worse than 72.88% of its industry peers.
SALME has a Quick Ratio of 0.96. This is a bad value and indicates that SALME is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.53, SALME is doing worse than 71.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.53
SALME.OL Yearly Current Assets VS Current LiabilitesSALME.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for SALME have decreased strongly by -95.00% in the last year.
SALME shows a decrease in Revenue. In the last year, the revenue decreased by -6.20%.
The Revenue has been growing by 238.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1700%
Revenue 1Y (TTM)-6.2%
Revenue growth 3Y238.62%
Revenue growth 5YN/A
Sales Q2Q%-46.54%

3.2 Future

Based on estimates for the next years, SALME will show a very strong growth in Earnings Per Share. The EPS will grow by 80.76% on average per year.
The Revenue is expected to grow by 50.27% on average over the next years. This is a very strong growth
EPS Next Y-140.34%
EPS Next 2Y52.79%
EPS Next 3Y79.43%
EPS Next 5Y80.76%
Revenue Next Year-8.13%
Revenue Next 2Y22.02%
Revenue Next 3Y46.13%
Revenue Next 5Y50.27%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SALME.OL Yearly Revenue VS EstimatesSALME.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
SALME.OL Yearly EPS VS EstimatesSALME.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SALME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 141.38 indicates a quite expensive valuation of SALME.
SALME's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. SALME is more expensive than 77.97% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of SALME to the average of the S&P500 Index (22.73), we can say SALME is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 141.38
SALME.OL Price Earnings VS Forward Price EarningsSALME.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SALME.OL Per share dataSALME.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as SALME's earnings are expected to grow with 79.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.79%
EPS Next 3Y79.43%

More info and screens

0

5. Dividend

5.1 Amount

SALME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SALMON EVOLUTION ASA

OSL:SALME (9/12/2025, 7:00:00 PM)

5.2

-0.05 (-0.95%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)08-19 2025-08-19/bmo
Earnings (Next)11-11 2025-11-11
Inst Owners21.67%
Inst Owner ChangeN/A
Ins Owners2.19%
Ins Owner ChangeN/A
Market Cap2.41B
Analysts85.33
Price Target8.62 (65.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-215.55%
Min EPS beat(2)-220.42%
Max EPS beat(2)-210.68%
EPS beat(4)1
Avg EPS beat(4)-422.53%
Min EPS beat(4)-1265.05%
Max EPS beat(4)6.04%
EPS beat(8)2
Avg EPS beat(8)-223.01%
EPS beat(12)5
Avg EPS beat(12)-150.61%
EPS beat(16)9
Avg EPS beat(16)-104.98%
Revenue beat(2)0
Avg Revenue beat(2)-30.39%
Min Revenue beat(2)-43.93%
Max Revenue beat(2)-16.84%
Revenue beat(4)1
Avg Revenue beat(4)-23.17%
Min Revenue beat(4)-43.93%
Max Revenue beat(4)1.98%
Revenue beat(8)3
Avg Revenue beat(8)-20.9%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.41%
PT rev (3m)-9.42%
EPS NQ rev (1m)-66.66%
EPS NQ rev (3m)-177.77%
EPS NY rev (1m)-2666.7%
EPS NY rev (3m)-2666.7%
Revenue NQ rev (1m)-17.17%
Revenue NQ rev (3m)-13.46%
Revenue NY rev (1m)-12.74%
Revenue NY rev (3m)-20.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 141.38
P/S 7.05
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.19
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)0.04
Fwd EY0.71%
FCF(TTM)-1.81
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.74
BVpS4.54
TBVpS4.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.15%
ROE -8.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.88%
FCFM N/A
ROA(3y)-2.76%
ROA(5y)-2.34%
ROE(3y)-3.94%
ROE(5y)-3.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.83%
GM growth 5YN/A
F-Score2
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 988.05%
Cap/Sales 235.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.96
Quick Ratio 0.53
Altman-Z 0.95
F-Score2
WACC7.83%
ROIC/WACCN/A
Cap/Depr(3y)4495.02%
Cap/Depr(5y)15899.7%
Cap/Sales(3y)642.51%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1700%
EPS Next Y-140.34%
EPS Next 2Y52.79%
EPS Next 3Y79.43%
EPS Next 5Y80.76%
Revenue 1Y (TTM)-6.2%
Revenue growth 3Y238.62%
Revenue growth 5YN/A
Sales Q2Q%-46.54%
Revenue Next Year-8.13%
Revenue Next 2Y22.02%
Revenue Next 3Y46.13%
Revenue Next 5Y50.27%
EBIT growth 1Y-161.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73454.1%
EBIT Next 3Y1493.28%
EBIT Next 5Y568.23%
FCF growth 1Y-44.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.05%
OCF growth 3YN/A
OCF growth 5YN/A